Healthcare - Biotechnology - NASDAQ - US
$ 1.22
-3.17 %
$ 104 M
Market Cap
-0.71
P/E
CASH FLOW STATEMENT
-88.3 M
OPERATING CASH FLOW
61.1 M
INVESTING CASH FLOW
-9.72 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Century Therapeutics, Inc.
| Net Income | -137 M |
| Depreciation & Amortization | 13 M |
| Capital Expenditures | -13.7 M |
| Stock-Based Compensation | 14.6 M |
| Change in Working Capital | 9.38 M |
| Others | 23 M |
| Free Cash Flow | -102 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (136.7) | (130.9) | (95.8) | (53.6) | (244.8) |
| Depreciation & Amortization | 13.0 | 8.4 | 3.7 | 1.4 | 0.2 |
| Deferred Income Tax | 0 | 0 | 0 | 4.7 | 0 |
| Stock Based Compensation | 14.6 | 10.7 | 4.7 | 0.9 | 0.1 |
| Other Operating Activities | 11.3 | 1.9 | 1.2 | 0.4 | 225.9 |
| Change in Working Capital | 9.4 | 123.9 | (2.8) | 4.9 | 2.3 |
| Cash From Operations | (88.3) | 14.1 | (89.0) | (41.3) | (16.2) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (13.7) | (30.6) | (45.0) | (9.8) | (2.5) |
| Other Items | 74.9 | 17.5 | (253.4) | (12.9) | (17.4) |
| Cash From Investing Activities | 61.1 | (13.1) | (298.3) | (22.8) | (19.8) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (10.2) | 0 | 0 | 9.7 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 196.2 | 38.0 | 74.8 |
| Cash From Financing Activities | (9.7) | 27.2 | 417.8 | 47.7 | 74.8 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (36.9) | 28.1 | 30.4 | (16.3) | 38.8 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (102.1) | (16.6) | (134.0) | (51.1) | (18.6) |